On a standalone basis for the 2025 settlement, revenue fell 1.8% year on year. In the same settlement, operating profit rose 382.1% and net profit rose 97.3%. WiseReport summarized that revenue declined slightly while cost reduction significantly improved profitability.
Gross profit growth was attributed to stable production and quality control for immunodiagnostic kits and molecular diagnostic products, along with the launch of Rapid Kits and POCT PCR equipment.
Per the business report, 2024 operating profit was KRW 490,575,285, turning positive from an operating loss of KRW 1,237,916,964 in 2023. Over the same period, net profit was KRW 1,277,163,652, reversing a net loss of KRW 1,354,522,329 in 2023.
On the 2025 settlement, WiseReport shows EPS of KRW 1,358, PER of 3.68x and PBR of 0.36x. The stock closed at KRW 5,000 on September 8, 2026, moving within a 52-week range of KRW 4,600 to KRW 13,760.
Its 3-month change was -39.02% and its 12-month change was -61.39%, with trading volume and trading value recorded at zero. The current share price at the time of writing is KRW 4,800.